Seeking Alpha

Mallinckrodt says its acute pain drug met primary endpoints in Phase III testing

  • Mallinckrodt (MNK +2.3%) trades up after saying its investigational drug MNK-795 showed statistically significant improvement in pain scores compared to a placebo during Phase III testing for treatment of acute pain following bunion removals.
  • The drug's New Drug Application was accepted by the FDA in July and granted priority review.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector